Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence

by A. V. Poletova, M. V. Shapina
Published 2020-10-01

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES

by M. V. Shapina, I. L. Khalif
Published 2017-11-01

Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice

by M. V. Shapina, B. A. Nanaeva
Published 2020-02-01

Vedolizumab for inflammatory bowel diseasesI

by Igor L. Khalif, M. V. Shapina
Published 2018-08-01

Certolizumab pegol in treatment of Crohn's disease with perianal lesions

by I L Khalif, B A Nanaeva, M V Shapina, A V Vardanyan
Published 2018-04-01

Certolizumab pegol in treatment of Crohn's disease with perianal lesions

by I.L. Khalif, B.A. Nanaeva, M.V. Shapina, A.V. Vardanyan
Published 2018-04-01

Colonic cytokines for severe ulcerative colitis

by Ye. A. Konovich, K. Ye. Shirokikh, I. L. Khalif, M. V. Shapina
Published 2018-08-01

Colonic growth factors (G-CSF, GM-CSF) and chemokines (MCP-1, MIP-1β) in severe ulcerative colitis

by Yevgeny A. Konovich, K. Ye. Shirokikh, M. V. Shapina, Igor L. Khalif
Published 2018-08-01

Skin diseases and inflammatory bowel diseases. Literature review

by T. L. Alexandrov, I. L. Khalif, A. Yu. Khalif, Z. R. Khismatullina, M. V. Shapina
Published 2020-05-01

Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study)

by L. . Khalif, M. V. Shapina, A. O. Golovenko, Ye. A. Belousova, Ye. Yu. Chashkova, A. V. Lakhin, O. V. Knyazev, A. Yu. Baranovsky, N. N. Nikolayeva, A. V. Tkachev
Published 2018-08-01

Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion

by D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeysh, M. V. Shapina, O. B. Shchukina
Published 2020-12-01

Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion

by D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina, O. B. Shchukina
Published 2020-09-01